LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01).

Authors :: Salar, A.
Domingo ‐ Domenech, E.
Panizo, C.
Nicolás, C.
Bargay, J.
Muntañola, A.
Canales, M.
Bello, J.
Sancho, J.
Tomás, J.
Rodriguez, M.
Peñalver, F.J.
Palomera, L.
Grande, C.
Sánchez ‐ Blanco, J.J.
Arranz, R.
Conde, E.
Garcia, M.
García, J.F.
Caballero, D.
Source :: Hematological Oncology; Jun2017 Supplement, Vol. 35, p147-148, 2p
Publication Year :: 2017

Full Text Access

Tools